Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00486330 · ClinicalTrials.gov registry record · NA
Pharmacokinetic Interactions Between Buprenorphine and Tipranavir/Ritonavir
A NA study of HIV Infections, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT00486330: Completed NA study of HIV Infections, sponsored by Yale University.
NCT00486330 is a NA study of HIV Infections that has completed, run by Yale University. The registered enrollment target is 12 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00486330, a NA study of HIV Infections, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The main purpose of this study is to examine the effect of tipranavir combined with ritonavir, medications for the treatment of HIV-infection, on buprenorphine/naloxone (BUP) in people who have been receiving the same dose of buprenorphine/naloxone for at least 3 weeks before study entry.
Primary Outcome
Non-compartmental methods were used for pharmacokinetic analysis. The area under the plasma drug concentration-time curve was estimated by linear-log trapezoidal rule at 24-hrs.
Conditions Studied
Interventions
- DRUG Buprenorphine, Tipranavir and ritonavir
Study Locations (1)
Connecticut
- Yale University School of Medicine AIDS Program - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2006-05 |
| Est. Completion | 2007-05 |
| Phase | NA |
What the finished NCT00486330 record still lists
NCT00486330 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (97% lower).
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Buprenorphine, Tipranavir and ritonavir is the first listed.
NCT00486330 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT00486330 about?
NCT00486330 is a clinical study titled "Pharmacokinetic Interactions Between Buprenorphine and Tipranavir/Ritonavir". The main purpose of this study is to examine the effect of tipranavir combined with ritonavir, medications for the treatment of HIV-infection, on buprenorphine/naloxone (BUP) in people who have been receiving the same dose of buprenorphine/naloxone for at least 3 weeks before study entry.
What is the current status of trial NCT00486330?
This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2006-05. Estimated completion is 2007-05.
What conditions does trial NCT00486330 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00486330?
The interventions under investigation include: Buprenorphine, Tipranavir and ritonavir (DRUG).
Who is sponsoring clinical trial NCT00486330?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00486330 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00486330's enrollment target sits among peer trials
12 519th of 542 higher than 18 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
RECRUITING · NA
-
Community-based Education, Navigation, and Support Intervention for Military Veterans
RECRUITING · NA
-
WiseApp for Spanish Speakers Living With HIV
RECRUITING · NA
-
Comprehensive HIV and Harm Prevention Via Telehealth
RECRUITING · NA
-
Substance Checking Outreach and Pre-Exposure Prophylaxis (PrEP) Engagement Study
RECRUITING · NA
-
Food as Medicine for HIV and Diabetes
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia